Professional Documents
Culture Documents
Judith Kwasa1, Deanna Cettomai1,2, Edwin Lwanya1, Dennis Osiemo1, Patrick Oyaro1, Gretchen L.
Birbeck3, Richard W. Price2, Elizabeth A. Bukusi1, Craig R. Cohen4, Ana-Claire L. Meyer1,2*
1 Center for Microbiology Research Kenya Medical Research Institute, Nairobi, Kenya, 2 Department of Neurology, University of California San Francisco, San Francisco,
California, United States of America, 3 Michigan State University, East Lansing, Michigan, United States of America, 4 Department of Obstetrics, Gynecology and
Reproductive Sciences, University of California San Francisco, San Francisco, California, United States of America
Abstract
Objective: To conduct a preliminary evaluation of the utility and reliability of a diagnostic tool for HIV-associated dementia
(HAD) for use by primary health care workers (HCW) which would be feasible to implement in resource-limited settings.
Background: In resource-limited settings, HAD is an indication for anti-retroviral therapy regardless of CD4 T-cell count.
Anti-retroviral therapy, the treatment for HAD, is now increasingly available in resource-limited settings. Nonetheless, HAD
remains under-diagnosed likely because of limited clinical expertise and availability of diagnostic tests. Thus, a simple
diagnostic tool which is practical to implement in resource-limited settings is an urgent need.
Methods: A convenience sample of 30 HIV-infected outpatients was enrolled in Western Kenya. We assessed the sensitivity
and specificity of a diagnostic tool for HAD as administered by a primary HCW. This was compared to an expert clinical
assessment which included examination by a physician, neuropsychological testing, and in selected cases, brain imaging.
Agreement between HCW and an expert examiner on certain tool components was measured using Kappa statistic.
Results: The sample was 57% male, mean age was 38.6 years, mean CD4 T-cell count was 323 cells/mL, and 54% had less
than a secondary school education. Six (20%) of the subjects were diagnosed with HAD by expert clinical assessment. The
diagnostic tool was 63% sensitive and 67% specific for HAD. Agreement between HCW and expert examiners was poor for
many individual items of the diagnostic tool (K = .03.65). This diagnostic tool had moderate sensitivity and specificity for
HAD. However, reliability was poor, suggesting that substantial training and formal evaluations of training adequacy will be
critical to enable HCW to reliably administer a brief diagnostic tool for HAD.
Citation: Kwasa J, Cettomai D, Lwanya E, Osiemo D, Oyaro P, et al. (2012) Lessons Learned Developing a Diagnostic Tool for HIV-Associated Dementia Feasible to
Implement in Resource-Limited Settings: Pilot Testing in Kenya. PLoS ONE 7(3): e32898. doi:10.1371/journal.pone.0032898
Editor: Jialin Charles Zheng, University of Nebraska Medical Center, United States of America
Received October 5, 2010; Accepted February 6, 2012; Published March 7, 2012
Copyright: 2012 Kwasa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Fulbright African Regional Research Program, American Academy of Neurology Foundation Practice Research Training
Fellowship, and Doris Duke International Clinical Research Fellowship. In addition this study was supported by the Fogarty International Clinical Research
Fellowship (5 R24 TW00798; 3 R24 TW00798-02S1) from the National Institutes of Health, Fogarty International Center through Vanderbilt University, the National
Cancer Institute, the National Institute on Drug Abuse, Office of the Director, National Institutes of Health and the National Institute of Mental Health. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: meyerac@sfgh.ucsf.edu
Introduction
HIV-associated dementia (HAD) is an indication for initiating
antiretroviral therapy regardless of CD4 T-cell count according to
World Health Organization (WHO) guidelines (a WHO Stage IV
diagnosis [1]. However, HAD is likely under-diagnosed in routine
clinical practice in resource-limited settings [2]. Furthermore,
HAD is still a clinically important disorder in resource-limited
settings where many individuals present with advanced HIV
disease. In research studies from sub-Saharan Africa, the
prevalence of HAD ranges from 2.5%54% [310]; these
estimates vary widely likely due to differences in the sampled
populations and methods for assessment of cognitive impairment.
In contrast, the incidence of HAD in more developed regions has
PLoS ONE | www.plosone.org
Procedures
A diagnostic tool was administered by a HCW. The results of
this tool were compared to an expert clinical assessment
performed by study staff which included: examination by a
physician, a neuropsychological test battery administered by
expert study staff, and computed tomography of the head when
clinically indicated. The results of the expert clinical assessment
were used to identify patients meeting a modification of the
Frascati criteria for HAD [24]. The diagnostic tool was also
administered by trained staff during the expert assessment to assess
reliability.
Methods
Objectives
The objective of this study was to conduct a preliminary
evaluation of the utility and reliability of a diagnostic tool for HAD
designed for use by non-physician primary HCW.
Participants
A convenience sample of 30 adults was recruited from an
outpatient HIV care and treatment program run by Family AIDS
Care and Education Services (FACES) in Kisumu, a city in
Western Kenya, between September and October 2009. Potential
participants were invited to participate when they presented for
clinical care. One participant who had time to participate in the
study (study activities took about 3 hours) was chosen each day by
clinic staff and referred to study staff. In addition, patients with
neurological findings were oversampled in order to assess the
PLoS ONE | www.plosone.org
Ethics Statement
The study protocol was approved by the University of
California San Francisco (UCSF) Committee on Human Research
and the National Ethical Review Committee (ERC) of the Kenya
Medical Research Institute (KEMRI). Written informed consent
was obtained from each participant.
Results
Expert Clinical Assessment
The mean age of the sample was 39 years and 57% were male.
The mean CD4 T-cell count was 323 cells/mL, 60% had WHO
Stage 3 or 4 disease, and 50% had less than a secondary school
education (Table 1). Nearly 23% (7/30) of participants had
moderate or severe depression using the Patient Assessment of
Health Questionnaire (PHQ9) [41]. In general, functional status
measures demonstrated mild impairments. There were no
significant differences in demographic, clinical, functional status
or psychiatric characteristics between individuals with and without
HAD though this should be interpreted with caution given small
sample sizes.
Among our pilot sample, 20% (6/30) were diagnosed with HAD
based on the expert clinical assessment. An additional 33% (10/
30) were classified as normal. The remaining 47% (14/30)
individuals were grouped and classified as mild neurocognitive
impairment. Among the individuals classified as normal, there
were five individuals with abnormal neurological examinations
potentially localizing to the central nervous system. Findings
included: (1) unsteady gait and asymmetric ataxia (left worse than
right); (2) multiple cranial neuropathies (III, IV, V, VI, VII, IX, X)
with subtle left sided weakness and left cerebellar signs; (3)
parkinsonism; (4) a large left retro-orbital mass, and (5) a history of
right-sided weakness with no objective findings on examination.
Of these individuals, three individuals were referred for computed
tomography (CT) of the head. The CT findings were as follows: (1)
Marked cerebellar volume loss including the middle cerebellar
peduncle and pons but sparing the medullary pyramids; (2)
periventricular hypothalamic lesion and marked edema, likely
CNS lymphoma, (3) diffuse volume loss and small caudate heads.
The individual with a left retro-orbital mass had a CT scan
3
Table 1. Baseline characteristics of study participants comparing individuals with and without HIV-associated dementia.
Overall (n = 30)
No dementia (n = 24)
HIV-associated dementia (n = 6)
Demographic Characteristics
Age [mean (SD)]
39 (10)
47 (6.8)
37 (10)
Male [% (n)]
57% (17)
50% (12)
83% (5)
Never Married
13% (4)
17% (4)
0%
Married
63% (19)
54% (13)
83% (5)
Widowed
20% (6)
21% (5)
17% (1)
Divorced/separated
4% (1)
4% (1)
0%
23% (7)
21% (5)
33% (2)
At least primary
27% (8)
29% (7)
17% (1)
Secondary
37% (11)
42% (10)
17% (1)
14% (4)
12% (2)
33% (2)
37% (11)
38% (9)
33% (2)
13% (4)
13% (3)
17% (1)
Stage 1
13% (4)
13% (3)
17% (1)
Stage 2
27% (8)
29% (7)
17% (1)
Stage 3
37% (11)
33% (8)
50% (3)
Stage 4
23% (7)
25% (6)
17 (1)
198 (150)
215 (157)
127 (103)
323 (211)
337 (227)
268 (134)
23% (7)
21% (5)
33% (2)
92 (20)
92 (22)
91 (4.1)
4 (0)
4 (0)
4 (0)
7.8 (0.7)
7.8 (0.7)
8 (0)
89(19)
97 (4)
87 (201)
82 (5.1)
80 (31)
89 (16)
12 (14)
13 (15)
12 (5.9)
Socio-economic status
Table 2. Comparison of mean raw scores on individual tests comprising neuropsychological test battery by level of cognitive
impairment among HIV-infected individuals.*
Normal
ANI, MND
HAD
(n = 6)
(n = 14)
(n = 6)
Mean
SD
Mean
SD
Mean
SD
Animals
20.8
(5.5)
16.6
(3.8)
14.8
(4.1)
First Names
23
(4.3)
23.1
(5.4)
19.3
(5.5)
Category Fluency
Executive Function
Color Trails 2{
118.8
(28.9)
159.2
(46.5)
169.5
(42.9)
Block Design
16.2
(7.3)
11.8
(2.5)
7.3
(3.3)
Digit Symbol
51.8
(12)
34.5
(10.9)
23
(14.0)
Color Trails 1{
51.2
(9.3)
76.3
(29.0)
99.3
(28.9)
13.8
(2.1)
12.2
(3.2)
11.2
(4.7)
52.8
(3.2)
45.1
(8.0)
41.3
(6.7)
AVLT Trial V
12.5
(1.4)
11.1
(2.0)
9.3
(2.7)
21.8
(4.8)
17.4
(8.2)
13.2
(6.9)
12.2
(1.7)
9.4
(2.9)
7.7
(2.3)
8.8
(1.8)
6.3
(3.6)
5.7
(2.9)
Attention/Working Memory
Digit Span
Visual and Verbal Learning
Motor Skills
Finger Tapper (D)
44.7
(5.7)
38.3
(5.7)
34.4
(10.1)
38.2
(6.4)
33.8
(4.1)
33.5
(7.7)
71.2
(10.3)
91.7
(25.6)
111.3
(27.8)
82.5
(12.3)
93.9
(14.5)
132.5
(30.2)
Timed Gait{
11
(1.5)
13.3
(2.3)
13.5
(2.8)
Batteries
International HIV Dementia Scale
11
(1.7)
9.9
(1.9)
8.5
(1.8)
27.5
(1.9)
27.1
(2,1)
26.5
(2.2)
*Four individuals with non-HIV related neurologic diagnoses that affected performance on neuropsychological tests were dropped from this analysis.
{Higher scores indicate worse performance. Abbreviations: ANI: Asymptomatic Neurocognitive Impairment; D = Dominant; HAD: HIV-associated dementia; MND: Mild
Neurocognitive Disorder; ND = Non-dominant.
doi:10.1371/journal.pone.0032898.t002
Figure 1. Comparison of mean standardized scores on individual neuropsychological tests comprising neuropsychological test
battery and a composite measure by level of cognitive impairment among HIV-infected individuals.
doi:10.1371/journal.pone.0032898.g001
Discussion
Expert Clinical Assessment
This convenience sample of individuals presenting for routine
clinical care in Kenya was comparable to larger community-based
samples from sub-Saharan Africa [4244]. In addition, during the
month that we were recruiting for this study, we encountered
several individuals with severe neurological disordershighlighting the importance of improving neurological training for primary
HIV healthcare workers in resource-limited settings.
Neuropsychological Test Battery and HAND. Mean raw
and standardized scores (Z-scores) on many tests in our
neuropsychological test battery demonstrated large magnitude
differences between individuals with and without HAND. Our
results demonstrated the typical pattern of HIV associated
cognitive impairment with one notable exception. Our results
were similar to prior studies in that we observed large differences
in scores in the domains of executive function (Block Design, Color
Trails 2,) speed of information processing (Digit Symbol, Color
Trails), and motor/psychomotor function (Grooved Pegboard,
Finger Tapper, and Timed Gait) [4549].
In contrast to previous studies, tests of motor or psychomotor
performance in the non-dominant hand did not demonstrate
larger magnitude differences in mean raw or standardized scores
and thus may not be more sensitive and reliable in diagnosing
PLoS ONE | www.plosone.org
Table 3. Agreement between non-physician health care worker and a expert examiner on cognitive tests in the diagnostic tool.
0.03
0.05
0.47
0.65
C8: Recall
0.25
0.32
0.26
doi:10.1371/journal.pone.0032898.t003
Conclusion
Pilot testing suggests that substantial training and formal
evaluations of training adequacy will be critical to enable primary
HCW to reliably administer a brief diagnostic tool for HAD that
contains cognitive tests and a neurological examination. Alternatively, selecting the simpler or more familiar components from
more sophisticated screening or diagnostic tools may improve the
7
Supporting Information
Appendix S1 HIV Dementia Diagnostic Tool.
Author Contributions
(DOC)
Acknowledgments
We would like to thank the medical officers, clinical officers, nurses, clinic/
community health assistants, staff and patients at Family AIDS Care and
Education Services for their participation. We would also like to thank the
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19. World Health Organization (2006) The world health report: working together
for health. http://www.who.int/whr/2006/whr06_en.pdf, Accessed 2010
September 1.
20. Jowi J (2007) Provision of Care to People with Epilepsy in Kenya. East African
Medical Journal 84: 9799.
21. Singh D, Joska J, Goodkin K, Lopez E, Myer L, et al. (2010) Normative scores
for a brief neuropsychological battery for the detection of HIV-associated
neurocognitive disorder (HAND) among South Africans. BMC Research Notes
3: 28.
22. Robertson KR, Nakasujja N, Wong M, Musisi S, Katabira E, et al. (2007)
Pattern of neuropsychological performance among HIV positive patients in
Uganda. BMC Neurol 7: 8.
23. World Health Organization (2008) Task shifting: rational redistribution of tasks
among health workforce teams: global recommendations and guidelines: http://
www.who.int/healthsystems/TTR-TaskShifting.pdf, Accessed: 2010 September
1.
24. Antinori A, Arendt G, Becker J, Brew B, Byrd D, et al. (2007) Updated research
nosology for HIV-associated neurocognitive disorders. Neurology 69:
17891799.
25. Chelune G, Heaton R, Lehman R (1986) Neuropsychological and personality
correlates of patients complaints of disability. In: Goldstein G, ed. Advances in
clinical neuropsychology. New York: Plenium Press. pp 95126.
26. Folstein M, Folstein S, McHugh P (1975) Mini-mental state. A practical
method for grading the cognitive state of patients for the clinician. J Psychiatr
Res Nov 12(3): 189198.
27. Katz S, Ford A, Moskowitz R, Jackson B, Jaffe M (1963) Studies of Illness in the
Aged. The Index of ADL: A standardized measure of biological and
psychosocial function. JAMA 185: 914919.
28. Lawton M, Brody E (1969) Assessment of older people: self-maintaining and
instrumental activities of daily living. Gerontologist 9: 179186.
29. RAND Health Appendix A Core Survey Instrument: The Medical Outcomes
Study 116 item core set of measures of functioning and well-being. http://www.
rand.org/content/dam/rand/www/external/health/surveys_tools/mos/mos_
core_survey.pdf. Accessed: 2008 May 25.
30. Schag C, Heinrich R, Ganz P (1984) Karnofsky Performance Status Revisited:
Reliability, Validity and Guidelines. Journal of Clinical Oncology 2: 187193.
31. Wechsler D (1997) WAIS-III: Administration and Scoring Manual: The
Psychological Corporation.
32. Lezak MD, Howieson DB, Loring DW, Hannay HJ, JS F, eds. (2004)
Neuropsychological Assessment. 4th ed. New York: Oxford University Press. pp
422429.
33. Maj M, Janssen R, Starace F, Zaudig M, Satz P, et al. (1994) WHO
Neuropsychiatric AIDS study, cross-sectional phase I. Study design and
psychiatric findings. Arch Gen Psychiatry 51: 3949.
34. Benedict RHB, ed. (1997) Brief Visual memory Test-Revised. 4th ed. Florida:
Psychological Assessment Resources, Inc.
35. Lafayette I (2003) Grooved Pegboard Users Manual. Lafayette, IN: Lafayette
Instrument Company, Inc.
36. PAR (1992) Finger Tapper Users Guide. Florida: Psychological Assessment
Resources, Inc.
37. Robertson KR, Parsons TD, Sidtis JJ, Hanlon Inman T, Robertson WT, et al.
(2006) Timed Gait test: normative data for the assessment of the AIDS dementia
complex. J Clin Exp Neuropsychol 28: 10531064.
38. Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, et al. (1999) Norms
for letter and category fluency: demographic corrections for age, education, and
ethnicity. Assessment 6: 147178.
39. Monsch AU, Bondi MW, Butters N, Salmon DP, Katzman R, et al. (1992)
Comparisons of verbal fluency tasks in the detection of dementia of the
Alzheimer type. Arch Neurol 49: 12531258.
40. Strauss E, Sherman E, Spreen O (2006) A Compendium of Neuropsychological
Tests: Administration, Norms, and Commentary. New York: Oxford University
Press Inc.
41. Monahan P, Shacham E, Reece M, Kroenke K, Ongor W, et al. (2008)
Validity/Reliability of PHQ-9 and PHQ-2 Depression Scales Among Adults
Living with HIV/AIDS in Western Kenya. Journal of General Internal
Medicine 24: 189197.
42. Birbeck GL, Chomba E, Kvalsund M, Bradbury R, Mangombe C, et al. (2009)
Antiretroviral adherence in rural Zambia: the first year of treatment availability.
Am J Trop Med Hyg 80: 669674.
43. Jarvis Joseph N, Lawn Stephen D, Vogt M, Bangani N, Wood R, et al. (2009)
Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral
Treatment Program in South Africa. Clin Infect Dis 48: 856862.
44. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, et al. (2007)
Asymptomatic serum cryptococcal antigenemia and early mortality during
antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929935.
45. Sacktor N (2002) The epidemiology of human immunodeficiency virusassociated neurological disease in the era of highly active antiretroviral therapy.
J Neurovirol 8: 115121.